Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Robert McQueen to Cost-Benefit Analysis

This is a "connection" page, showing publications Robert McQueen has written about Cost-Benefit Analysis.

 
Connection Strength
  
 
 
3.594
  
  1. Carlson JJ, Brouwer ED, Kim E, Wright P, McQueen RB. Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation. Value Health. 2020 12; 23(12):1523-1533.
    View in: PubMed
    Score: 0.594
  2. McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD. Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations. Pharmacoeconomics. 2018 08; 36(8):957-971.
    View in: PubMed
    Score: 0.510
  3. DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb; 24(2):171-180.
    View in: PubMed
    Score: 0.186
  4. Zemplenyi A, Leonard J, DiStefano MJ, Anderson KE, Wright GC, Mendola ND, Nair K, McQueen RB. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. Pharmacoeconomics. 2024 Mar; 42(3):319-328.
    View in: PubMed
    Score: 0.184
  5. McQueen RB, Anderson KE, Levy JF, Carlson JJ. Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable? Pharmacoeconomics. 2023 03; 41(3):321-327.
    View in: PubMed
    Score: 0.174
  6. Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB. A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. Pharmacoeconomics. 2020 11; 38(11):1201-1218.
    View in: PubMed
    Score: 0.149
  7. Synnott PG, McQueen RB, Ollendorf DA, Campbell JD, Pearson SD. The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease. J Manag Care Spec Pharm. 2020 Jun; 26(6):782-785.
    View in: PubMed
    Score: 0.145
  8. McQueen RB, Geno Rasmussen C, Waugh K, Frohnert BI, Steck AK, Yu L, Baxter J, Rewers M. Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado. Diabetes Care. 2020 07; 43(7):1496-1503.
    View in: PubMed
    Score: 0.144
  9. McQueen RB, Whittington MD, Chapman RH, Kumar VM, Campbell JD. Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". Pharmacoeconomics. 2019 07; 37(7):963-964.
    View in: PubMed
    Score: 0.136
  10. Whittington MD, McQueen RB, Ollendorf DA, Chapman RH, Kumar VM, Synnott PG, Agboola F, Campbell JD. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. J Manag Care Spec Pharm. 2019 Jan; 25(1):80-87.
    View in: PubMed
    Score: 0.131
  11. McQueen RB, Breton MD, Craig J, Holmes H, Whittington MD, Ott MA, Campbell JD. Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 and Type 2 Diabetes in England. J Diabetes Sci Technol. 2018 09; 12(5):992-1001.
    View in: PubMed
    Score: 0.125
  12. McQueen RB, Padula WV, Campbell JD. A Call for Open-Source Cost-Effectiveness Analysis. Ann Intern Med. 2018 04 03; 168(7):528-529.
    View in: PubMed
    Score: 0.125
  13. Padula WV, McQueen RB, Pronovost PJ. Can Economic Model Transparency Improve Provider Interpretation of Cost-effectiveness Analysis? Evaluating Tradeoffs Presented by the Second Panel on Cost-effectiveness in Health and Medicine. Med Care. 2017 11; 55(11):909-911.
    View in: PubMed
    Score: 0.121
  14. Padula WV, McQueen RB, Pronovost PJ. Finding Resolution for the Responsible Transparency of Economic Models in Health and Medicine. Med Care. 2017 11; 55(11):915-917.
    View in: PubMed
    Score: 0.121
  15. van Boven JF, McQueen RB, Price DB. COPD case finding: effective, but also cost-effective? Lancet Respir Med. 2016 10; 4(10):e49.
    View in: PubMed
    Score: 0.112
  16. McQueen RB, Nair KV, Vollmer TL, Campbell JD. Incorporating real-world clinical practice in multiple sclerosis economic evaluations. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(6):869-72.
    View in: PubMed
    Score: 0.104
  17. McQueen RB, Breton MD, Ott M, Koa H, Beamer B, Campbell JD. Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada. J Diabetes Sci Technol. 2015 Aug 14; 10(2):366-77.
    View in: PubMed
    Score: 0.104
  18. Campbell JD, McQueen RB, Libby AM, Spackman DE, Carlson JJ, Briggs A. Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information. Med Decis Making. 2015 07; 35(5):596-607.
    View in: PubMed
    Score: 0.098
  19. McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Libby AM, Campbell JD. Association between glycated hemoglobin and health utility for Type 1 diabetes. Patient. 2014; 7(2):197-205.
    View in: PubMed
    Score: 0.093
  20. Rind DM, McQueen RB, Herron-Smith S, Herce-Hagiwara B, Gutierrez E, Campbell JD, Fluetsch N, Pearson SD. The effectiveness and value of tezepelumab for severe asthma. J Manag Care Spec Pharm. 2022 May; 28(5):577-580.
    View in: PubMed
    Score: 0.041
  21. Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma. JAMA Netw Open. 2019 02 01; 2(2):e190035.
    View in: PubMed
    Score: 0.033
  22. Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia. JAMA Pediatr. 2018 12 01; 172(12):1161-1168.
    View in: PubMed
    Score: 0.033
  23. Whittington MD, McQueen RB, Campbell JD. Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies. JAMA Pediatr. 2018 05 01; 172(5):409-410.
    View in: PubMed
    Score: 0.031
  24. Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017 Feb; 118(2):220-225.
    View in: PubMed
    Score: 0.028
  25. Dilokthornsakul P, McQueen RB, Chaiyakunapruk N, Spackman E, Watanabe JH, Campbell JD. Value of Information in Asia: Concepts, Current Use, and Future Directions. Value Health Reg Issues. 2016 May; 9:99-104.
    View in: PubMed
    Score: 0.027
  26. Campbell JD, McQueen RB, Briggs A. The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Ann Am Thorac Soc. 2014 Feb; 11 Suppl 2:S105-11.
    View in: PubMed
    Score: 0.023
  27. Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Am J Manag Care. 2013 Apr; 19(4):278-85.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)